We employed multiple methodologies, each with a specific focus on tumor and mesothelial cells, to investigate how disrupting Notch signaling by MRK-003, a GSI inhibitor, impairs Notch-Jagged2-mediated cross-talk between tumor cells and mesothelial cells. The gene discussed is JAG2; the disease is neoplasm.